Gastrointestinal bleeding related to liver cirrhosis Medical Services in China

Gastrointestinal bleeding related to liver cirrhosis—commonly termed variceal hemorrhage—is a life-threatening complication arising from portal hypertension secondary to advanced chronic liver disease. Cirrhosis induces structural distortion and fibrotic scarring of hepatic parenchyma, leading to increased resistance to portal blood flow. This results in elevated portal venous pressure (>10 mmHg), triggering the formation of portosystemic collateral vessels—most critically esophageal and gastric varices. These fragile, dilated submucosal veins lack supportive tissue and are prone to rupture under hemodynamic stress (e.g., transient increases in intra-abdominal or intrathoracic pressure), causing acute, often massive upper GI bleeding. Less commonly, bleeding may originate from portal hypertensive gastropathy or ectopic varices (e.g., duodenal, colonic). Epidemiologically, approximately 5–15% of patients with compensated cirrhosis develop varices annually; among those with established varices, the annual risk of first bleed is 5–15%, rising to 30–40% in those with large varices or red wale signs. Mortality remains high: 15–20% within 6 weeks of an initial episode, with rebleeding occurring in 60% of untreated survivors within 1 year. Key risk factors include Child-Pugh class C or MELD score ≥15, large varices, active alcohol use, coagulopathy (low platelets, prolonged INR), bacterial infection (e.g., spontaneous bacterial peritonitis), and ongoing portal hyperdynamic circulation. Beyond acute mortality, recurrent bleeding profoundly impairs quality of life—patients experience persistent fatigue, anxiety about sudden hemorrhage, dietary restrictions (e.g., avoidance of coarse foods), reduced physical activity, social withdrawal, and significant caregiver burden. Hospitalizations, endoscopic surveillance, and long-term pharmacotherapy (e.g., non-selective beta-blockers) contribute to psychological distress and financial strain. Early diagnosis via screening gastroscopy in newly diagnosed cirrhosis is standard of care; management hinges on multidisciplinary coordination between hepatology, gastroenterology, interventional radiology, and critical care. Without timely intervention—including endoscopic band ligation, pharmacologic vasoconstriction (terlipressin/octreotide), antibiotics, and definitive portal pressure reduction (e.g., TIPS)—outcomes deteriorate rapidly. Patient education on symptom recognition (e.g., hematemesis, melena, syncope), strict adherence to prophylactic therapy, and abstinence from alcohol and NSAIDs are essential components of holistic care.

Gastrointestinal bleeding in patients with liver cirrhosis is a life-threatening complication primarily driven by portal hypertension and its downstream vascular consequences. The most common cause is esophageal and gastric variceal hemorrhage, resulting from portosystemic collateral vessel formation due to increased resistance to hepatic blood flow through fibrotic and regenerating nodules. As portal pressure rises (typically >12 mmHg), splanchnic vasodilation and hyperdynamic circulation further exacerbate shunting, leading to progressive varix formation—particularly at the gastroesophageal junction (esophageal varices) and fundus (gastric varices). Variceal rupture occurs when wall tension exceeds structural integrity, often precipitated by transient increases in portal pressure or direct mucosal trauma. Non-variceal causes include portal hypertensive gastropathy (PHG), characterized by mosaic-like mucosal erythema, telangiectasias, and friability due to chronic venous congestion and microvascular shunting; and gastric antral vascular ectasia (GAVE), though less frequent, may be associated with advanced cirrhosis and coagulopathy. Less common etiologies include stress-related mucosal damage (Curling’s or Cushing’s ulcers), Mallory-Weiss tears secondary to forceful retching or vomiting, and concurrent peptic ulcer disease—often potentiated by NSAID use or Helicobacter pylori infection.

Triggers of acute bleeding include abrupt increases in intra-abdominal or intrathoracic pressure (e.g., straining during defecation, coughing, or lifting), alcohol binges (which induce splanchnic vasodilation and impair platelet function), acute bacterial infections (especially spontaneous bacterial peritonitis, which amplifies systemic inflammation and endothelial dysfunction), and procedural interventions such as endoscopy without adequate hemodynamic stabilization. Rapid diuresis or large-volume paracentesis without albumin infusion can provoke circulatory dysfunction and precipitate variceal rupture. Additionally, anticoagulant or antiplatelet therapy—even at prophylactic doses—significantly lowers the threshold for hemorrhage in this vulnerable population.

Established risk factors encompass both disease-related and patient-specific variables. Advanced Child-Pugh class (B or C) and Model for End-Stage Liver Disease (MELD) score ≥10 strongly correlate with bleeding incidence and mortality. Large variceal size (>5 mm), presence of red wale marks (indicating high rupture risk), and active variceal bleeding on prior endoscopy are endoscopic predictors. Coagulopathy—manifested by prolonged INR, thrombocytopenia (<100 × 10⁹/L), and reduced fibrinogen—arises from impaired hepatic synthesis, splenic sequestration, and uremic platelet dysfunction in renal impairment. Concomitant hepatorenal syndrome or acute-on-chronic liver failure (ACLF) markedly worsens prognosis. Comorbidities including diabetes mellitus (promoting microangiopathy), chronic kidney disease (exacerbating platelet dysfunction), and cardiovascular disease (limiting compensatory hemodynamic reserve) further elevate risk.

Genetic factors play a modulatory role rather than direct causation. Polymorphisms in genes regulating collagen metabolism (e.g., COL1A1, TIMP1) influence fibrosis progression rate and thus indirectly affect variceal development timing. Variants in endothelial nitric oxide synthase (eNOS) may predispose to exaggerated splanchnic vasodilation and earlier onset of portal hypertension. Hemochromatosis (HFE gene mutations), alpha-1 antitrypsin deficiency (SERPINA1), and Wilson disease (ATP7B) represent inherited metabolic disorders that, if untreated, lead to cirrhosis and subsequent variceal risk—but these are etiologic precursors rather than bleeding-specific genetic determinants. No monogenic ‘bleeding susceptibility’ locus has been validated; however, polygenic risk scores incorporating coagulation factor variants (e.g., F5 Leiden, though rare in cirrhosis cohorts) are under investigation.

Environmental factors significantly contribute to both cirrhosis development and bleeding vulnerability. Chronic excessive alcohol consumption remains the predominant environmental driver—not only accelerating fibrogenesis but also directly impairing platelet adhesion and thrombin generation. Exposure to aflatoxin B1 (in mold-contaminated grains) synergizes with hepatitis B virus to promote rapid fibrosis progression. Socioeconomic determinants—including limited access to hepatology care, delayed endoscopic screening, inconsistent adherence to non-selective beta-blockers (e.g., propranolol, carvedilol), and unregulated use of over-the-counter NSAIDs or herbal hepatotoxins (e.g., kava, comfrey)—compound bleeding risk. Geographic disparities in hepatitis B/C prevalence and vaccination coverage also shape regional patterns of cirrhosis-related hemorrhage. Importantly, smoking is independently associated with increased variceal formation and rebleeding, likely via nicotine-induced endothelial injury and upregulation of vascular endothelial growth factor (VEGF).

Gastrointestinal bleeding related to liver cirrhosis—most commonly due to esophageal or gastric varices—is a life-threatening complication of advanced chronic liver disease. It arises from portal hypertension, which develops as fibrotic scarring impedes hepatic sinusoidal blood flow, leading to collateral vessel formation in the gastroesophageal junction and fundus. Early recognition of subtle clinical cues is critical for timely intervention and mortality reduction.

Early symptoms are often nonspecific and easily overlooked. Patients may report mild, intermittent epigastric discomfort or vague upper abdominal fullness, particularly after meals. Fatigue, decreased exercise tolerance, and unexplained lightheadedness upon standing (orthostatic presyncope) may reflect subclinical hypovolemia or early anemia. Some individuals experience recurrent, self-limited episodes of coffee-ground emesis or maroon-colored stools—suggestive of low-volume, slow bleeding that undergoes partial gastric digestion or colonic transit. Mild, persistent iron-deficiency anemia—evidenced by pallor, exertional dyspnea, or tachycardia at rest—may be the sole initial finding on routine blood work. Importantly, up to 30% of patients with high-risk varices remain asymptomatic until their first major hemorrhage, underscoring the necessity of surveillance endoscopy in all compensated and decompensated cirrhotics.

Typical symptoms reflect acute, significant upper gastrointestinal hemorrhage. Hematemesis—bright red or clotted blood vomitus—is highly specific for active proximal bleeding and occurs in approximately 60–70% of variceal bleeds. Melena—black, tarry, foul-smelling stools—results from upper GI bleeding with sufficient transit time for hemoglobin degradation by colonic bacteria; it typically indicates blood loss ≥50–100 mL. In cases of rapid, massive hemorrhage, hematochezia (passage of bright red or maroon blood per rectum) may occur due to rapid colonic transit, mimicking lower GI bleeding. Acute hypovolemic signs dominate the clinical picture: tachycardia (>100 bpm), orthostatic hypotension (systolic BP drop ≥20 mmHg or diastolic ≥10 mmHg upon standing), delayed capillary refill (>3 seconds), cool clammy skin, and altered mental status ranging from confusion to obtundation. Syncope or near-syncope is common in patients with preexisting autonomic dysfunction or cardiovascular comorbidity.

Accompanying symptoms reflect underlying cirrhosis and systemic consequences of hemorrhage. Jaundice (scleral icterus, dark urine, pale stools) reflects impaired bilirubin conjugation and excretion. Ascites—often newly worsened or tense—may develop or exacerbate due to intravascular volume depletion triggering sodium retention and renal vasoconstriction. Hepatic encephalopathy may acutely deteriorate following bleeding, driven by increased nitrogen load from blood protein digestion, systemic inflammation, and reduced hepatic clearance. Patients frequently exhibit spider angiomas, palmar erythema, leukonychia, testicular atrophy, or muscle wasting. Coagulopathy manifests as easy bruising, mucosal oozing, or prolonged bleeding after minor trauma—attributable to impaired synthesis of clotting factors (II, VII, IX, X), thrombocytopenia (from splenic sequestration and thrombopoietin deficiency), and qualitative platelet dysfunction.

Complications are frequent and carry high morbidity and mortality. Rebleeding occurs in 60% of untreated patients within 1–2 weeks and accounts for ~40% of in-hospital deaths. Hypovolemic shock may progress to multiorgan failure—including acute kidney injury (prerenal azotemia progressing to hepatorenal syndrome), acute respiratory distress syndrome, and ischemic hepatitis. Bacterial infections—particularly spontaneous bacterial peritonitis and pneumonia—are markedly increased post-bleed due to gut translocation, immune paralysis, and invasive procedures; infection independently doubles mortality risk. Acute-on-chronic liver failure (ACLF) may be precipitated, characterized by rapid deterioration in liver synthetic function (INR >2.0, bilirubin >12 mg/dL), coagulopathy, and extrahepatic organ failures. Portosystemic encephalopathy can become refractory, and stress-related mucosal disease (Curling ulcers) may cause secondary non-variceal bleeding.

Diagnosis relies on integration of clinical assessment, laboratory testing, and urgent endoscopy. Initial labs include complete blood count (revealing acute anemia, thrombocytopenia), INR/PT (prolonged in synthetic dysfunction), serum creatinine and electrolytes (assessing renal perfusion), liver enzymes (AST/ALT ratio >2 suggestive of alcoholic cirrhosis), albumin, total bilirubin, and lactate (marker of tissue hypoperfusion). Type and crossmatch must be initiated immediately. Nasogastric lavage may help localize upper vs. lower source but has limited sensitivity and specificity. Urgent upper gastrointestinal endoscopy—performed within 12 hours of presentation—is the gold standard for diagnosis and therapy: it confirms variceal morphology (size, red wale marks, cherry-red spots), grades severity (small vs. large), identifies active bleeding or stigmata of recent hemorrhage (e.g., white nipple sign), and enables therapeutic interventions (band ligation, sclerotherapy, cyanoacrylate injection). Contrast-enhanced CT angiography or MR portography may be used if endoscopy is contraindicated or inconclusive, revealing varices, portosystemic collaterals, and portal vein patency/thrombosis.

Differential diagnosis must exclude other causes of upper GI bleeding in cirrhotic patients. Non-variceal sources include peptic ulcer disease (more common in NSAID or H. pylori–positive patients), Mallory-Weiss tears (associated with forceful retching), erosive gastritis, and Dieulafoy lesions. Portal hypertensive gastropathy presents with chronic, occult bleeding and characteristic mosaic-pattern mucosa on endoscopy but rarely causes massive hemorrhage. Gastric antral vascular ectasia (GAVE, 'watermelon stomach') may cause iron-deficiency anemia and obscure bleeding, especially in older cirrhotics with autoimmune features. Lower GI sources—diverticular disease, angiodysplasia, ischemic colitis—must be considered when melena is absent and hematochezia predominates, though variceal bleeding can mimic this pattern. Rarely, malignancy (e.g., gastric or esophageal carcinoma) or aortoenteric fistula must be ruled out, particularly in patients with prior aortic surgery or progressive weight loss. Crucially, coagulopathy alone does not cause variceal rupture but significantly increases bleeding risk and impairs hemostasis once hemorrhage begins—thus, correcting coagulopathy (e.g., vitamin K, fresh frozen plasma, prothrombin complex concentrate) is adjunctive but never a substitute for definitive endoscopic control.

Gastrointestinal bleeding in patients with liver cirrhosis is most commonly attributable to portal hypertension–induced esophageal or gastric varices, though other contributors—including portal hypertensive gastropathy, gastric antral vascular ectasia (GAVE), and coagulopathy—must be considered. Management requires a multidisciplinary, risk-stratified approach integrating hemodynamic stabilization, endoscopic intervention, pharmacotherapy, and long-term secondary prevention. Prompt recognition and coordinated care are critical, as variceal hemorrhage carries a 20% in-hospital mortality rate and a high risk of rebleeding within six weeks without appropriate prophylaxis.

Conservative treatment forms the initial cornerstone of management and begins with immediate resuscitation. Patients require strict bed rest, continuous cardiorespiratory monitoring, and large-bore intravenous access. Crystalloid infusion is initiated cautiously to avoid volume overload and precipitating hepatic encephalopathy; goal-directed fluid resuscitation targets systolic blood pressure ≥90 mmHg and urine output ≥30 mL/h, while avoiding overtransfusion. Packed red blood cells are transfused only to maintain hemoglobin between 7–9 g/dL (restrictive strategy), as liberal transfusion increases mortality in cirrhotic patients. Fresh frozen plasma, platelets, and vitamin K may be administered selectively based on coagulation profile (INR >2.5) and active bleeding, but routine correction is discouraged unless invasive procedures are planned. Nasogastric aspiration helps assess ongoing upper GI bleeding but is not routinely recommended for diagnosis alone. Airway protection is prioritized in altered-mental-status patients to prevent aspiration pneumonia.

Pharmacologic therapy is integral at all stages. Intravenous octreotide (50 mcg bolus followed by 50 mcg/h continuous infusion) or terlipressin (2 mg IV bolus, then 1–2 mg every 4–6 hours) is initiated immediately upon suspicion of variceal bleeding to reduce portal pressure and splanchnic blood flow. These agents significantly improve hemostasis rates when combined with endoscopy. Antibiotic prophylaxis—typically intravenous ceftriaxone 1 g daily for 7 days—is mandatory to reduce bacterial infections, which occur in up to 40% of admitted patients and independently increase mortality. For secondary prophylaxis, non-selective beta-blockers (NSBBs) such as propranolol (starting at 10–20 mg twice daily, titrated to resting heart rate 55–60 bpm or maximal tolerated dose) or carvedilol (6.25 mg once daily, titrated to 12.5 mg daily) are first-line to lower hepatic venous pressure gradient (HVPG). Endoscopic variceal ligation (EVL) remains the gold-standard primary endoscopic modality for acute variceal hemorrhage and for eradication of medium-to-large esophageal varices. Band ligation is repeated every 2–4 weeks until varices are obliterated, followed by surveillance every 6–12 months. In gastric varices—particularly isolated gastric varices type 2 (IGV2) or gastroesophageal varices (GOV2)—cyanoacrylate injection (e.g., N-butyl-2-cyanoacrylate) is superior to EVL due to higher obliteration rates and lower rebleeding risk.

Surgical and interventional options are reserved for refractory or recurrent bleeding uncontrolled by endoscopic and medical therapy. Transjugular intrahepatic portosystemic shunt (TIPS) is indicated in patients with Child–Pugh class A or B cirrhosis who fail endoscopic and pharmacologic control, or experience early rebleeding (<72 hours post-index bleed). Polytetrafluoroethylene (PTFE)-covered stents have reduced shunt dysfunction and improved 1-year patency (>85%) compared to bare-metal stents. Surgical shunts (e.g., distal splenorenal shunt) are rarely performed today due to high operative morbidity and limited availability of experienced hepatobiliary surgeons. Liver transplantation remains the definitive curative intervention for eligible patients with decompensated cirrhosis and recurrent variceal bleeding; it addresses both the underlying liver disease and portal hypertension. Pre-transplant TIPS may serve as a bridge in select cases.

China offers distinct advantages in the comprehensive management of cirrhosis-related GI bleeding. First, China’s national endoscopy networks—supported by the Chinese Society of Gastroenterology—ensure rapid access to high-volume centers where advanced endoscopic techniques (including cyanoacrylate injection, balloon-occluded retrograde transvenous obliteration [BRTO], and EUS-guided coil+glue injection) are standardized and widely available. Second, cost-effective, domestically manufactured somatostatin analogues and covered TIPS stents have improved affordability and accessibility across tier-2 and tier-3 cities. Third, integrated hepatology–endoscopy–interventional radiology teams operate under unified clinical pathways endorsed by the National Health Commission, minimizing delays in triage and escalation. Fourth, China’s robust real-world data infrastructure enables dynamic risk modeling (e.g., incorporating spleen stiffness measurement via 2D-SWE and platelet count to predict variceal bleeding) that informs personalized prophylaxis strategies. Finally, telemedicine platforms facilitate longitudinal follow-up and medication adherence monitoring in rural populations, reducing late presentation and improving secondary prevention compliance.

Recovery and long-term management emphasize patient education and structured surveillance. Patients must abstain absolutely from alcohol and NSAIDs, and avoid constipation (via fiber supplementation and lactulose if needed) to prevent rises in portal pressure. Dietary counseling should promote adequate protein intake (1.2–1.5 g/kg/day) while monitoring for early signs of hepatic encephalopathy. All patients require lifelong NSBB therapy unless contraindicated (e.g., asthma, bradycardia, hypotension), with regular assessment of HVPG response where feasible. Surveillance endoscopy is recommended every 6–12 months after variceal eradication, or annually in those with persistent small varices. Vaccination against hepatitis A and B is reinforced, and metabolic comorbidities (e.g., diabetes, obesity) are actively managed to mitigate further liver injury. Psychosocial support—including counseling for anxiety related to rebleeding risk—and caregiver training in recognizing prodromal symptoms (melena, hematemesis, dizziness, orthostatic hypotension) are essential components of holistic recovery. With optimized multidisciplinary care, five-year survival following a first variceal bleed exceeds 50% in well-selected patients, underscoring the importance of timely, protocol-driven intervention.